09:46 AM EDT, 04/11/2024 (MT Newswires) -- Teva Pharmaceutical Industries ( TEVA ) unit Teva Pharmaceuticals said Thursday that a late-stage trial in China assessing the efficacy and safety of Ajovy to prevent migraine in adults achieved the primary endpoint and all secondary endpoints.

The company said the drug "significantly" decreased the number of migraine days seen per month and showed "superior efficacy" compared with placebo.

The data also showed Ajovy was "safe and well tolerated," the company said, adding that the results were consistent with previous late-stage data for the drug, which was already approved for the prevention of migraine in adults in the US in 2018 and in the EU in 2019.

In the Chinese trial, 365 people were randomized to get 225 milligrams of Ajovy subcutaneously once a month for three months or a single dose of 675 milligrams once a quarter, or placebo, the company said.

Price: 13.67, Change: -0.18, Percent Change: -1.3